Showing 1 - 3 results of 3 for search 'Yuanxun Yang', query time: 0.05s Refine Results
  1. 1
    First-in-human study to assess the safety, tolerability, pharmacokinetics and immunogenicity of DS002, an anti-nerve growth factor monoclonal antibody

    First-in-human study to assess the safety, tolerability, pharmacokinetics and immunogenicity of DS002, an anti-nerve growth factor monoclonal antibody by Tingting Ma, Bei Cao, Lei Huang, Yuanxun Yang, Yan Geng, Pinhao Xie, Yu Zhao, Hui Lin, Kun Wang, Chunhe Wang, Runbin Sun, Juan Li

    Published 2022
    Connect to this object online.
    Book
    Save to List
    Saved in:
  2. 2
    SHR2285, the first selectively oral FXIa inhibitor in China: Safety, tolerability, pharmacokinetics and pharmacodynamics combined with aspirin, clopidogrel or ticagrelor

    SHR2285, the first selectively oral FXIa inhibitor in China: Safety, tolerability, pharmacokinetics and pharmacodynamics combined with aspirin, clopidogrel or ticagrelor by Tingting Ma, Yanli Dong, Lei Huang, Yuanxun Yang, Yan Geng, Fei Fei, Pinhao Xie, Yu Zhao, Hui Lin, Zeyu Yang, Yun Jin, Xitong Ju, Runbin Sun, Juan Li

    Published 2022
    Connect to this object online.
    Book
    Save to List
    Saved in:
  3. 3
    The first selective VAP-1 inhibitor in China, TT-01025-CL: safety, tolerability, pharmacokinetics, and pharmacodynamics of single- and multiple-ascending doses

    The first selective VAP-1 inhibitor in China, TT-01025-CL: safety, tolerability, pharmacokinetics, and pharmacodynamics of single- and multiple-ascending doses by Yuanxun Yang, Lei Yu, Zejuan Sheng, Hui Lin, Zuyi Weng, Wei Song, Bei Cao, Yu Zhao, Yingsheng Gao, Shumao Ni, Huimin Wang, Tingting Ma, Lei Huang, Caixia Sun, Juan Li

    Published 2024
    Connect to this object online.
    Book
    Save to List
    Saved in:

Search Tools: